Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had ...

This exploratory genomic analysis of data from the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials represents a comprehensive evaluation of the clinical and molecular characteristics of late ...

The approval was predicated on Merck and Eisai showing that response rate data was matched by an improvement in survival in a follow-up trial, and that data from the KEYNOTE-775 study has now come in.

Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome Using pretreatment tumor samples, bulk DNA was analyzed via whole-exome ...